Identifiers
Calneurin sense presents high-severity safety concerns, primarily as a carcinogen (GHS H350) and a potent contact sensitizer. It is also classified as a skin corrosive (H314) and shows acute oral toxicity in rats (LD50 142 mg/kg bw). These hazards indicate significant health risks upon exposure, requiring stringent handling protocols. For business and formulation decisions, this substance should be treated as a high-risk material, potentially limiting its use in consumer products unless rigorously controlled. The carcinogenicity classification alone necessitates comprehensive risk assessment and regulatory scrutiny before any commercial application.
The hazard classifications and toxicology findings for calneurin sense should be interpreted as complementary evidence of a systemic and multi-route toxicant. The GHS H350 carcinogenicity classification aligns with the SCOEL assessment indicating a potential lack of threshold for systemic genotoxicity, while the positive sensitization and skin corrosion findings point to direct dermal hazards. Together, these data suggest that both local and systemic effects are possible, with the respiratory tract identified as a specific target. For regulatory and safety assessments, this integrated view supports a precautionary approach, emphasizing the need for strict exposure controls across all routes.
Material exposure routes for calneurin sense include dermal, inhalation, and oral pathways. Dermal exposure is particularly concerning due to its classification as a skin corrosive and potent contact sensitizer, with skin notation supported. Inhalation is a critical route given the respiratory tract is a specific target for carcinogenicity and genotoxicity. Oral exposure is relevant based on the rat LD50 of 142 mg/kg bw, indicating high acute toxicity. These routes collectively pose risks for systemic effects, including effects on the liver, spleen, and kidneys, as well as fertility and developmental toxicity. Occupational settings require comprehensive monitoring to prevent exposure.
Relevant risk-management measures for calneurin sense include engineering controls to minimize inhalation and dermal exposure, such as local exhaust ventilation and enclosed processes. Personal protective equipment (PPE) is essential, including chemical-resistant gloves, protective clothing, and respiratory protection, given the skin corrosion and sensitization hazards. Given the carcinogenicity and genotoxicity concerns, exposure should be reduced to as low as reasonably achievable (ALARA). Medical surveillance for respiratory and dermal effects may be warranted. These controls are critical for regulatory compliance and worker safety, especially in manufacturing or handling environments.
Key safety evidence gaps for calneurin sense include the absence of quantitative occupational exposure limits (e.g., PEL, TLV) and incomplete data on dose-response relationships for carcinogenicity, particularly for upper respiratory tract tumors. Additionally, the threshold for systemic genotoxicity remains unresolved, and no specific NOAEL values were provided for fertility or developmental toxicity. These gaps hinder precise risk characterization and the establishment of safe handling levels. Before commercial or formulation decisions, these data should be obtained through targeted toxicological studies or regulatory submissions to support a robust safety assessment.